Review
Infectious Diseases
Chienhsiu Huang, Ihung Chen, Lichen Lin
Summary: Combination therapy with daptomycin plus ceftaroline may reduce mortality in patients with methicillin-resistant Staphylococcus aureus bacteremia. The combination therapy group had similar in-hospital mortality, duration of bacteremia, and adverse event rate compared to the monotherapy group, but had lower bacteremia recurrence.
Article
Immunology
Matthew P. Cheng, Alexander Lawandi, Guillaume Butler-Laporte, Samuel De L'Etoile-Morel, Katryn Paquette, Todd C. Lee
Summary: The study aimed to determine the efficacy of synergistic treatment with daptomycin when given with either cefazolin or cloxacillin for the treatment of MSSA BSI. Results showed that adjunctive daptomycin therapy did not shorten the duration of bacteremia when added to standard-of-care treatment for MSSA BSIs, and should not be routinely considered.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Infectious Diseases
Cheng-En Tsai, Chia-Jui Yang, Yu-Chung Chuang, Jann-Tay Wang, Wang-Huei Sheng, Yee-Chun Chen, Shan-Chwen Chang
Summary: This study aimed to determine the synergistic effects of combining CPT with DAP, VAN, or LNZ against different MRSA strains. The results showed that the CPT-DAP combination exhibited significant synergistic bactericidal effects, while the CPT-VAN and CPT-LNZ combinations did not show synergistic activity. Therefore, DAP may be a better choice for combination therapy with CPT in the treatment of MRSA infections.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
(2022)
Article
Infectious Diseases
Ashley Barlow, Emily L. Heil, Kimberly C. Claeys
Summary: This study compared the efficacy of vancomycin and daptomycin/ceftaroline in treating MRSA bloodstream infections, with the latter showing superior clinical outcomes in terms of duration of infection, recurrence rate, severe adverse events, and in-hospital mortality.
INFECTIOUS DISEASES AND THERAPY
(2021)
Review
Pharmacology & Pharmacy
Masaru Samura, Yuki Kitahiro, Sho Tashiro, Hiromu Moriyama, Yuna Hamamura, Isamu Takahata, Rina Kawabe, Yuki Enoki, Kazuaki Taguchi, Yoshio Takesue, Kazuaki Matsumoto
Summary: This systematic review and meta-analysis compares the efficacy of daptomycin and vancomycin in adult patients with bacteremia caused by methicillin-resistant Staphylococcus aureus (MRSA) with a vancomycin minimum inhibitory concentration (MIC) > 1 mu g/mL. The results show that daptomycin treatment is associated with lower mortality and higher treatment success compared to vancomycin, regardless of the vancomycin MIC test method used. Daptomycin should be considered as a treatment option for MRSA bacteremia with a vancomycin MIC > 1 mu g/mL, especially in patients with intermediate- and high-risk bacteremia sources.
Article
Pharmacology & Pharmacy
Wesley D. Kufel, Katie A. Parsels, Bruce E. Blaine, Jeffrey M. Steele, Rahul Mahapatra, Kristopher M. Paolino, Stephen J. Thomas
Summary: This study aimed to evaluate the effectiveness and safety of vancomycin plus ceftaroline for persistent methicillin-resistant Staphylococcus aureus bacteremia (MRSAB). The results showed that this regimen may be an effective and well-tolerated salvage option for persistent MRSAB.
Article
Immunology
Marin L. Schweizer, Kelly Richardson, Mary S. Vaughan Sarrazin, Michihiko Goto, Daniel J. Livorsi, Rajeshwari Nair, Bruce Alexander, Brice F. Beck, Michael P. Jones, Mireia Puig-Asensio, Daniel Suh, Madeline Ohl, Eli N. Perencevich
Summary: Among patients with methicillin-resistant Staphylococcus aureus bloodstream infections, switching to daptomycin is associated with lower 30-day mortality, especially when done within 3 days of initial vancomycin receipt. However, switching to daptomycin at any time during the first hospitalization did not significantly affect 30-day mortality.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Infectious Diseases
Patricia Garcia, Miriam Moscoso, M. Carmen Fernandez, Victor Fuentes-Valverde, Astrid Perez, German Bou
Summary: This study compared the efficacy of ceftaroline fos-amil with approved therapies for treating experimental MRSA bacteremia. Ceftaroline fosamil was found to be as effective as vancomycin and daptomycin, indicating its potential for treating difficult-to-treat S. aureus bacteremia.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
(2023)
Article
Infectious Diseases
Tanner M. Johnson, Kyle C. Molina, Matthew A. Miller, Tyree H. Kiser, Misha Huang, Scott W. Mueller
Summary: Complicated methicillin-resistant Staphylococcus aureus bloodstream infections, especially those with delayed culture clearance, have high mortality rates. Combination therapy with daptomycin and ceftaroline (DAP + CPT) shows potential for better outcomes compared to standard of care in treating these infections, with lower rates of clinical failure observed in patients receiving DAP + CPT.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
(2021)
Article
Immunology
Warren Rose, Michael Fantl, Matthew Geriak, Victor Nizet, George Sakoulas
Summary: Literature has shown the effectiveness of combination antimicrobial therapy in treating refractory MRSA bacteremia, but considerations need to be made on which regimens are more beneficial, potential harms, and which patients can benefit from more aggressive treatment. In addition, combination therapy for MRSA bacteremia does not need to be uniform throughout the treatment course, with options for early intensive treatment and later consolidation therapy.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Infectious Diseases
Yu-Chung Chuang, Hsin-Yi Lin, Jia-Ling Yang, Chi-Ying Lin, Sung-Hsi Huang, Jann-Tay Wang, Yee-Chun Chen, Shan-Chwen Chang
Summary: This study found that a high dose of daptomycin can improve the survival rate of patients with VRE bloodstream infections, but it is also associated with highly elevated creatine kinase.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
(2022)
Article
Microbiology
Robert E. Weber, Stephan Fuchs, Franziska Layer, Anna Sommer, Jennifer K. Bender, Andrea Thurmer, Guido Werner, Birgit Strommenger
Summary: GWAS identified MprF P314L and L826F mutations as significantly associated with DAP resistance in clinical S. aureus isolates, indicating convergent evolution. Rare genetic variants were also found within mprF and putative candidate genes, while no genetic variants were associated with CPT resistance.
FRONTIERS IN MICROBIOLOGY
(2021)
Article
Immunology
Courtney N. Nichols, Lynn C. Wardlow, Kelci E. Coe, Mohammad Mahdee E. Sobhanie
Summary: This study found no significant difference in the composite outcome of 60-day bacteremia recurrence, readmission, or inpatient infection-related mortality for patients with MRSA bacteremia retained on combination therapy versus those de-escalated to monotherapy.
OPEN FORUM INFECTIOUS DISEASES
(2021)
Article
Immunology
Miquel Pujol, Jose-Maria Miro, Evelyn Shaw, Jose-Maria Aguado, Rafael San-Juan, Mireia Puig-Asensio, Carles Pigrau, Esther Calbo, Miguel Montejo, Regino Rodriguez-Alvarez, Maria-Jose Garcia-Pais, Vicente Pintado, Rosa Escudero-Sanchez, Joaquin Lopez-Contreras, Laura Morata, Milagros Montero, Marta Andres, Juan Pasquau, Maria-del-Mar Arenas, Belen Padilla, Javier Murillas, Alfredo Jover-Saenz, Luis-Eduardo Lopez-Cortes, Graciano Garcia-Pardo, Oriol Gasch, Sebastian Videla, Pilar Hereu, Cristian Tebe, Natalia Pallares, Mireia Sanllorente, Maria-Angeles Dominguez, Jordi Camara, Anna Ferrer, Ariadna Padulles, Guillermo Cuervo, Jordi Carratala
Summary: The study found that daptomycin plus fosfomycin provided a slightly higher treatment success rate for MRSA bacteremia and endocarditis compared to daptomycin alone, but this difference was not statistically significant. The antibiotic combination was associated with lower rates of microbiological failure and complicated bacteremia, but was also more frequently linked to adverse events.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Public, Environmental & Occupational Health
Yu-Chung Chuang, Jann-Tay Wang, Jia-Ling Yang, Chi-Ying Lin, Sung-Hsi Huang, Yee-Chun Chen, Shan-Chwen Chang
Summary: Combining daptomycin with beta-lactam for the treatment of vancomycin-resistant Enterococcus (VRE) bacteremia significantly improves the composite clinical success rate. This approach is particularly effective when high-dose daptomycin is used and VRE shows a high minimum inhibitory concentration (MIC) for daptomycin.
JOURNAL OF INFECTION AND PUBLIC HEALTH
(2022)